Status:

UNKNOWN

Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome

Lead Sponsor:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Conditions:

Metabolic Syndrome

Eligibility:

All Genders

30-75 years

Brief Summary

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the hepatic complication of the metabolic syndrome of insulin resistance. In some patients, the disease can progress into steatohepatitis...

Eligibility Criteria

Inclusion

  • metabolic syndrome with 3 out of 5 criteria (ATP III definition)

Exclusion

  • alcohol intake \> 20g/day (women), \> 30g/day (men)
  • chronic liver disease of other cause: viral hepatitis (HBV, HCV), Wilson's disease, haemochromatosis, alpha1 anti-trypsin deficiency, drug-induced, ...
  • decompensated cirrhosis (Child-Pugh 3)
  • body weight \> 120 Kg

Key Trial Info

Start Date :

March 1 2006

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 1 2010

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT00399932

Start Date

March 1 2006

End Date

May 1 2010

Last Update

September 18 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

StLuc University Hospital

Brussels, Belgium, 1200

Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome | DecenTrialz